Xtandi takes fight to prostate cancer rivals with survival dataPfizer and Astellas have new survival data for their prostate cancer drug Xtandi that could help it fend Share XXtandi takes fight to prostate cancer rivals with survival datahttps://pharmaphorum.com/news/xtandi-takes-fight-to-prostate-cancer-rivals-with-survival-data/
AZ and MSD’s Lynparza gets fast prostate cancer FDA reviewThe FDA has granted AstraZeneca/MSD’s PARP-targeting drug Lynparza a fast review in prostate cancer, following hot on the Share XAZ and MSD’s Lynparza gets fast prostate cancer FDA reviewhttps://pharmaphorum.com/news/az-and-msds-lynparza-gets-fast-prostate-cancer-fda-review/
Clovis takes PARP prostate cancer pole position with fast FDA review of RubracaThe FDA has granted a fast review for Clovis Oncology’s Rubraca PARP drug in certain patients with prostate Share XClovis takes PARP prostate cancer pole position with fast FDA review of Rubracahttps://pharmaphorum.com/news/clovis-takes-parp-prostate-cancer-pole-position-with-fast-fda-review-of-rubraca/
AZ sells ex-US rights to old cancer drugs Arimidex and CasodexFor several years AstraZeneca has been selling off rights to its older drugs to raise cash as it Share XAZ sells ex-US rights to old cancer drugs Arimidex and Casodexhttps://pharmaphorum.com/news/az-sells-ex-us-rights-to-old-cancer-drugs-arimidex-and-casodex/
Xtandi catches up with Erleada in castration-sensitive prostate cancerPfizer and Astellas have bagged FDA approval for Xtandi in metastatic castration-sensitive prostate cancer (CSPC), cancelling out a Share XXtandi catches up with Erleada in castration-sensitive prostate cancerhttps://pharmaphorum.com/news/xtandi-catches-up-with-erleada-in-castration-sensitive-prostate-cancer/
Merck & Co’s Keytruda shows promise with prostate cancer ‘super responders’A small proportion of men with advanced prostate cancer, who have exhausted all other treatment options, were ‘super Share XMerck & Co’s Keytruda shows promise with prostate cancer ‘super responders’https://pharmaphorum.com/news/merck-cos-keytruda-shows-promise-with-prostate-cancer-super-responders/
FDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallThe FDA has approved Johnson & Johnson’s prostate cancer drug Erleada (apalutamide) for patients whose prostate cancer has Share XFDA approves J&J’s prostate cancer drug Erleada in new use, as Zytiga sales fallhttps://pharmaphorum.com/news/fda-approves-jjs-prostate-cancer-drug-erleada-in-new-use-as-zytiga-sales-fall/
AZ/MSD’s Lynparza sees positive results in prostate cancerAstraZeneca and MSD have announced positive phase III results for their PARP inhibitor Lynparza (olaparib) in metastatic castration-resistant Share XAZ/MSD’s Lynparza sees positive results in prostate cancerhttps://pharmaphorum.com/news/az-msds-lynparza-sees-positive-results-in-prostate-cancer/
Bayer aims at J&J and Pfizer with new prostate cancer drugThe FDA has approved Bayer and Orion’s prostate cancer drug darolutamide in the early stages of the disease Share XBayer aims at J&J and Pfizer with new prostate cancer drughttps://pharmaphorum.com/news/bayer-aims-at-jj-and-pfizer-with-new-prostate-cancer-drug/
